Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-03
2006-01-03
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235500, C514S266210, C514S266220, C514S266400, C544S119000, C544S284000, C544S292000, C540S575000
Reexamination Certificate
active
06982260
ABSTRACT:
This invention provides quinazolines that are useful for treating cell proliferative diseases and disorders, such as cardiovascular diseases, infections, cancers, autoimmune diseases, gout, kidney disease, and neurodegenerative diseases and disorders such as Alzheimer's disease. We have now discovered a group of 2-arylamino-7-(alkyl)oxy-8-alkylquinazolines and 8-alkyl-2-arylamino-quinazoline 2,7-diamines that are potent inhibitors of cyclin-dependent kinases (cdks). The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention also provides pharmaceutical formulations comprising at least one of the quinazoline compounds together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The invention further provide useful intermediates generated during the production of the quinazoline compounds.
REFERENCES:
patent: 4734418 (1988-03-01), Yokoyama et al.
patent: 5411963 (1995-05-01), Dreikorn et al.
patent: 0107398 (1983-09-01), None
patent: WO 98/33798 (1998-08-01), None
patent: WO 2001/038315 (2001-05-01), None
patent: WO 2002/022604 (2002-03-01), None
patent: WO 2004/026829 (2002-04-01), None
patent: WO 2002/050065 (2002-06-01), None
patent: WO 2002/057259 (2002-07-01), None
patent: WO 2002/059111 (2002-08-01), None
patent: WO 2002/062789 (2002-08-01), None
patent: WO 2002/066461 (2002-08-01), None
patent: WO 2002/068415 (2002-09-01), None
patent: WO 2004/065378 (2004-08-01), None
Elslager, E. et. al., “Synthesis and Antimalarial Effects . . . ”, J. Med. Chem., 1981, vol. 24, No. 2, pp. 127-140.
Gran Heinicke, et al. Chemical Abstract, Beillstein Reg. No. 5518665, Feb. 12, 1993.
Arteaga, C., “Blockade Of The Epidermal Growth Factor Receptor Tyrosine Suppresses Tumorigenesis In MMTV/Neu + MMTV/TGF-α Bigenic Mice,”Proceedings of the National Academy of Sciences Of The United States Of America, 2000, 9609-9614, vol. 97, No. 17.
Bathini, Y., et al., “Synthesis Of Substituted Quinazolines,”Tetrahedron Letters, 2002, 1-2, vol. 43.
Benson, D., et al., “GenBank,”Nucleic Acids Ressearch, 2000, 15-18, vol. 28, No. 1.
Dermatakis, A., “ATP-Competitive Inhibitors Of Cyclin-Dependent Kinases,”Frontiers of Biotechnology&Pharmaceuticals, 2002, 125-156, vol. 3.
Di Gennaro, E., et al., “Critical Role Of Both p27KIP1and p21CIP1/WAF1In The Antiproliferative Effect Of ZD1839 (‘Iressa’), An Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Head And Neck Squamous Carcinoma Cells,”Journal of Cellular Physiology, 2003, 139-150, vol. 195, No. 1.
Geller, J., et al., “P21Cip1Is A Critical Mediator Of The Cytotoxic Action Of Thymidylate Synthase Inhibitors In Colorectal Carcinoma Cells,”Cancer Research, 2004, 6296-6303, vol. 64.
Hennequin, L., et al., “Novel 4-Anilinoquinazolines With C-7 Basic Side Chains: Design And Structure Activity Relationship Of A Series Of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors,”Journal of Medicinal Chemistry, 2002, 1300-1312, vol. 45, No. 6.
Rewcastle, G., et al., “Synthesis of 4-(Phenylamino)Pyrimidine Derivatives As ATP-Competitive Protein Kinase Inhibitors With Potential For Cancer Chemotherapy,” Current Organic Chemistry, 2000, 679-706, vol. 4, No. 7.
Sgambato, A., et al., “Targeted Inhibition Of The Epidermal Growth Factor Receptor-Tyrosine Kinase By ZD1839 (‘Iressa’) Induces Cell-cycle Arrest And Inhibits Proliferation In Prostate Cancer Cells,”Journal Of Cellular Physiology, 2004, 97-105, vol. 201.
Shewchuk, L., et al., “Binding Mode Of The 4-Anilinoquinazoline Class Of Protein Kinase Inhibitor: X-ray Crystallographic Studies Of 4-Anilinoquinazolines Bound To Cyclin-Dependent Kinase 2 And p38 Kinase,”Journal of Medicinal Chemistry, 2000, 133-138, vol. 43, No. 1.
Yano, S., et al., “EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa®),” Japanese Journal of Pharmacology, 2003, 491-497, vol. 122, No. 6.
Barvian Mark Robert
Bathini Yadagiri
Dobrusin Ellen Myra
Kaltenbronn James Stanley
Micetich Ronald George
Hsu Wendy L.
Kifle Bruck
Warner-Lambert & Company
Zielinski Bryan C.
LandOfFree
Quinazolines and their use for inhibiting cyclin-dependent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolines and their use for inhibiting cyclin-dependent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolines and their use for inhibiting cyclin-dependent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3547881